Catalent, Inc. (CTLT)
| Market Cap | 17.67B |
| Revenue (ttm) | 4.70B |
| Net Income (ttm) | 486.90M |
| Shares Out | 179.21M |
| EPS (ttm) | 3.22 |
| PE Ratio | 30.59 |
| Forward PE | 22.68 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 323,650 |
| Open | 99.41 |
| Previous Close | 100.76 |
| Day's Range | 98.42 - 100.57 |
| 52-Week Range | 86.34 - 142.64 |
| Beta | 1.38 |
| Analysts | Buy |
| Price Target | 140.92 (+42.9%) |
| Earnings Date | May 3, 2022 |
About CTLT
Catalent, Inc., together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates through four segments: Biologics, Softgel and Oral Technologies, Oral and Specialty Delivery, and Clinical Supply Services. The Softgel and Oral Technologies segment provides formulation, development, and manufacturing services for soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary ...
Financial Performance
In 2021, Catalent's revenue was $4.00 billion, an increase of 29.22% compared to the previous year's $3.09 billion. Earnings were $585.00 million, an increase of 164.71%.
Financial StatementsAnalyst Forecast
According to 22 analysts, the average rating for CTLT stock is "Buy." The 12-month stock price forecast is 140.92, which is an increase of 42.89% from the latest price.
News
Catalent Shares Jump As Investors Cheer Revised, Better Than Expected FY22 Outlook
Catalent Inc (NYSE: CTLT) reported Q3 FY22 sales of $1.27 billion, +21% Y/Y as reported, or 23% in constant currency, edging out analysts' average expectation of $1.22 billion. Adjusted EPS of $1.04, co...
Catalent (CTLT) Q3 Earnings Beat Estimates, FY22 View Up
Catalent's (CTLT) robust performance across most of its segments drives its third-quarter fiscal 2022 top line.
Catalent (CTLT) Tops Q3 Earnings and Revenue Estimates
Catalent (CTLT) delivered earnings and revenue surprises of 10.64% and 4.38%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Catalent, Inc. Reports Third Quarter Fiscal 2022 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient tr...
Should You Buy Catalent (CTLT) Ahead of Earnings?
Catalent (CTLT) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Catalent (CTLT) Reports Next Week: Wall Street Expects Earnings Growth
Catalent (CTLT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Catalent (CTLT) is Poised to Beat Earnings Estimates Again
Catalent (CTLT) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Catalent's (CTLT) Latest Manufacturing Suites to Boost Capacity
Catalent's (CTLT) latest site expansion is expected to significantly boost its business.
Catalent, Inc. Announces Third Quarter Fiscal Year 2022 Earnings Conference Webcast
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the leading global provider of advanced delivery technologies, development, manufacturing and clinical supply solutions for drugs, biologics, cell and gene the...
Catalent's (CTLT) Latest Buyout to Expand Its Global Footprint
Catalent's (CTLT) latest acquisition is likely to significantly enhance its global Biologics business.
Stocks Like Catalent and PerkinElmer Are Benefiting From Biotech's 'Gold Rush' — Here's Why
Beyond the catchy biotech names splashed across the headlines, experts say medical stocks in the background, like Catalent and PerkinElmer, are maybe more likely to strike it rich. Investor's Business D...
Here's Why Catalent (CTLT) is a Strong Momentum Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Catalent's (CTLT) New Project Completion Expands Global Footprint
Catalent's (CTLT) latest facility transformation is likely to significantly enhance the global Biologics business.
Catalent, Inc. to Present at the KeyBanc Life Sciences & MedTech Investor Forum
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better patient treatments acro...
Is There A Better Pick Over West Pharmaceutical Services Stock?
We believe that Catalent stock, a global solutions provider for drugs, biologics, gene therapies, and consumer healthcare products, currently is an attractive pick over West Pharmaceutical Services, bes...
Catalent Publishes Third Annual Corporate Responsibility Report
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling biopharma, cell, gene, and consumer health partners to optimize development, launch, and supply of better pati...
Reasons to Retain Catalent (CTLT) Stock in Your Portfolio
Catalent's (CTLT) robust facility expansion activities and a slew of strategic deals raise optimism on the stock.
Catalent's (CTLT) New Tie-Up to Provide Better Patient Access
Catalent's (CTLT) latest collaboration is expected to enable it to provide customers access to the TFF technology.
Catalent (CTLT) Down 3.4% Since Last Earnings Report: Can It Rebound?
Catalent (CTLT) reported earnings 30 days ago. What's next for the stock?
Edenbridge Pharmaceuticals Announces the Launch of DARTISLA ODT
PARSIPPANY, N.J.--(BUSINESS WIRE)--Edenbridge Pharmaceuticals, LLC (“Edenbridge”) today announced that DARTISLA ODT (glycopyrrolate) is now available by prescription in the United States through Phil, t...
Got $5,000? These 3 Growth Stocks Are Trading Near Their 52-Week Lows
It takes guts to catch a falling knife, but sometimes the reward is worth the risk.
Catalent (CTLT) Q2 Earnings Top Estimates, FY22 View Up
Catalent's (CTLT) robust performance across most of its segments drives its second-quarter fiscal 2022 top line.
Catalent (CTLT) Surpasses Q2 Earnings and Revenue Estimates
Catalent (CTLT) delivered earnings and revenue surprises of 7.14% and 5.05%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Catalent's Q2 Earnings Beat Street View, Lifts FY22 Guidance
Catalent Inc CTLT has reported Q2 FY22 sales of $1.22 billion, +34% Y/Y as reported, or 35% in constant currency, edging out analysts' average expectation of $1.15 billion. [LIVE NOW ON YOUTUBE] Click H...
Catalent, Inc. Reports Second Quarter Fiscal 2022 Results
SOMERSET, N.J.--(BUSINESS WIRE)--Catalent, Inc. (NYSE: CTLT), the global leader in enabling pharma, biotech, and consumer health partners to optimize development, launch, and supply of better patient tr...